Gilead Sciences (GILD) Q2 2025 10-Q Quarterly Report
Filed: Aug 7, 2025Period ending Jun 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Gilead Sciences (GILD) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 7, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Gilead Sciences Q2 2025 10-Q Analysis
Management Discussion & Analysis
- • No quarterly revenue or profitability data disclosed in provided MD&A text
- • No segment or product line performance details included
- • No information on cash position, operating cash flow, or capital deployment changes
- • No management commentary on outlook, guidance, or headwinds presented
Risk Factors
- • New risk: FDA "boxed warning" on CAR T therapies in Jan 2024 for secondary T-cell malignancies, impacting Yescarta and Tecartus labeling
- • Updated regulatory risk: IRA increasing 2023-25 Medicare discounts and rebates, reducing profitability through new Part D payment rules
- • Legal risk: Uncertain outcome of litigation and enforcement actions around 340B contract pharmacy integrity initiative, including recent court decisions
- • Operational risk: Supply chain disruption risks for cell therapies due to reliance on certified apheresis centers and complex manufacturing needs
- • Financial risk: Sales dependent on 3 wholesalers accounting for ~90% U.S. distribution, causing volatile quarterly revenues from inventory mismatches
Gilead Sciences Q2 2025 Quarterly FinancialsXBRL
Revenue
$7.1B
▲ +1.8% YoY▲ +6.2% QoQ
Net Income
$2.0B
▲ +21.4% YoY▲ +49.0% QoQ
Operating Margin
34.9%
▼ -309bp YoY▲ +138bp QoQ
Net Margin
27.7%
▲ +447bp YoY▲ +795bp QoQ
EPS (Diluted)
$1.57
▲ +21.7% YoY▲ +51.0% QoQ
Operating Cash Flow
$827M
▼ -37.6% YoY▼ -52.9% QoQ
Source: XBRL data from Gilead Sciences Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Gilead Sciences Quarterly Reports
Get deeper insights on Gilead Sciences
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.